SANGAMO THERAPEUTICS, INC 8-K

What Happened
Sangamo Therapeutics, Inc. announced and furnished a press release reporting its financial results for the quarter ended March 31, 2026. The company filed an 8-K on May 14, 2026 to disclose the results of operations and financial condition; the press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Disclosure: Press release announcing the financial results furnished as Exhibit 99.1; the filing also includes the Interactive XBRL cover page (Exhibit 104).
• Signature: Report signed by Scott B. Willoughby, Chief Legal Officer and Corporate Secretary.

Why It Matters
This 8-K notifies investors that Sangamo has publicly reported its latest quarterly earnings and financial condition; the press release (Exhibit 99.1) will contain the specific revenue, expense, cash position and management commentary that can affect the stock. Investors should review the attached press release for the detailed financial figures and any forward-looking statements or operational updates.